322 related articles for article (PubMed ID: 34786591)
1. A Comparison of PROPr and EQ-5D-5L Value Sets.
Pan T; Mulhern B; Viney R; Norman R; Hanmer J; Devlin N
Pharmacoeconomics; 2022 Mar; 40(3):297-307. PubMed ID: 34786591
[TBL] [Abstract][Full Text] [Related]
2. A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample.
Rencz F; Brodszky V; Janssen MF
Value Health; 2023 Jul; 26(7):1045-1056. PubMed ID: 36804583
[TBL] [Abstract][Full Text] [Related]
3. Understanding the measurement relationship between EQ-5D-5L, PROMIS-29 and PROPr.
Mulhern BJ; Pan T; Norman R; Tran-Duy A; Hanmer J; Viney R; Devlin NJ
Qual Life Res; 2023 Nov; 32(11):3147-3160. PubMed ID: 37347395
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany.
Klapproth CP; Sidey-Gibbons CJ; Valderas JM; Rose M; Fischer F
Value Health; 2022 May; 25(5):824-834. PubMed ID: 35500951
[TBL] [Abstract][Full Text] [Related]
5. Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.
Nikl A; Janssen MF; Jenei B; Brodszky V; Rencz F
Pharmacoeconomics; 2024 May; 42(5):583-603. PubMed ID: 38416366
[TBL] [Abstract][Full Text] [Related]
6. Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy.
Xu RH; Ma B; Xin H; Zhang H; Zeng Y; Luo N; Dong D
Health Qual Life Outcomes; 2023 Nov; 21(1):123. PubMed ID: 37968716
[TBL] [Abstract][Full Text] [Related]
7. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
8. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
9. Psychometric properties of the PROMIS Preference score (PROPr) in patients with rheumatological and psychosomatic conditions.
Klapproth CP; Fischer F; Merbach M; Rose M; Obbarius A
BMC Rheumatol; 2022 Mar; 6(1):15. PubMed ID: 35249554
[TBL] [Abstract][Full Text] [Related]
10. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
11. Methodological similarities and variations among EQ-5D-5L value set studies: a systematic review.
Poudel N; Fahim SM; Qian J; Garza K; Chaiyakunapruk N; Ngorsuraches S
J Med Econ; 2022; 25(1):571-582. PubMed ID: 35416095
[TBL] [Abstract][Full Text] [Related]
12. Utilities Estimated from PROMIS Scales for Cost-Effectiveness Analyses in Stroke.
Thompson NR; Lapin BR; Katzan IL
Med Decis Making; 2023 Aug; 43(6):704-718. PubMed ID: 37401739
[TBL] [Abstract][Full Text] [Related]
13. Cross-sectional validation of the PROMIS-Preference scoring system by its association with social determinants of health.
Hanmer J
Qual Life Res; 2021 Mar; 30(3):881-889. PubMed ID: 33161483
[TBL] [Abstract][Full Text] [Related]
14. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.
Mulhern B; Feng Y; Shah K; Janssen MF; Herdman M; van Hout B; Devlin N
Pharmacoeconomics; 2018 Jun; 36(6):699-713. PubMed ID: 29476363
[TBL] [Abstract][Full Text] [Related]
15. Scale agreement, ceiling and floor effects, construct validity, and relative efficiency of the PROPr and EQ-5D-3L in low back pain patients.
Klapproth CP; Fischer F; Rose M
Health Qual Life Outcomes; 2023 Sep; 21(1):107. PubMed ID: 37759272
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PROMIS Preference Scoring System (PROPr) in Patients Undergoing Hemodialysis or Kidney Transplant.
Zhang J; Dewitt B; Tang E; Breitner D; Saqib M; Li D; Siddiqui R; Edwards N; Peipert JD; Hays RD; Hanmer J; Mucsi I
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1328-1336. PubMed ID: 34272256
[TBL] [Abstract][Full Text] [Related]
17. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
Pickard AS; Gooderham M; Hartz S; Nicolay C
J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional validation of the PROMIS-Preference scoring system.
Hanmer J; Dewitt B; Yu L; Tsevat J; Roberts M; Revicki D; Pilkonis PA; Hess R; Hays RD; Fischhoff B; Feeny D; Condon D; Cella D
PLoS One; 2018; 13(7):e0201093. PubMed ID: 30063733
[TBL] [Abstract][Full Text] [Related]
19. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
20. New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey.
Sullivan T; Turner RM; Derrett S; Hansen P
Value Health; 2021 Sep; 24(9):1308-1318. PubMed ID: 34452711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
